ETFs Unicycive Therapeutics, Inc.

UNCY

US90466Y2028

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-19 EDT			5-day change	1st Jan Change
3.510 ^USD	+4.46%		-13.33%	-39.17%

10-01	Unicycive Therapeutics, Inc. Appoints Meredith Manning to its Board of Directors, Each of the Audit, Compensation, and Nominating and Corporate Governance Committees, and Chairperson of the Nominating and Corporate Governance Committee	CI
09-29	Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate	CI

ETFs positioned on Unicycive Therapeutics, Inc.

Name	YTD change	Weight	AuM
VANGUARD MORNINGSTAR U.S. TOTAL MARKET INDEX ETF - CAD	+15.24%	0%	14,144 M€
UPAR ULTRA RISK PARITY ETF - USD	-2.01%	0%	59 M€
ELM MARKET NAVIGATOR ETF - USD	+7.10%	0%	594 M€
VANGUARD CONSERVATIVE ETF PORTFOLIO - CAD	+3.28%	0%	688 M€
RPAR RISK PARITY ETF - USD	+0.04%	0%	580 M€
DEFINED DURATION 20 ETF - USD	+10.38%	0%	19 M€
CAMBRIA TAX AWARE ETF - USD	+6.17%	0%	26 M€
VANGUARD BALANCED ETF PORTFOLIO - CAD	+6.79%	0%	4,204 M€
CLEARSHARES OCIO ETF - DISTRIBUTING - USD	+7.82%	0%	176 M€
AB US EQUITY ETF - USD	+9.90%	0%	727 M€
DEFINED DURATION 5 ETF - USD	+0.06%	0%	18 M€
CAMBRIA US EW ETF - USD	+9.82%	0%	194 M€
CAMBRIA GLOBAL EW ETF - USD	+7.54%	0%	146 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+11.36%	0%	513 M€
CAMBRIA ENDOWMENT STYLE ETF - USD	+11.44%	0%	156 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+12.38%	-.--%	62 M€

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Employees

Sector

Biotechnology & Medical Research

More about the company